All GLG News Analyses Filed Under: Business of Medicine

Allscripts was a darling while they could show growth of their EMR product over the past years, but a majority of this growth was likely due to their partnership with IDX. Misys has been struggling in the Healthcare marketplace for a number of years, showing no growth and an erosion of their Practice...

Large pharma and the several larger biopharmas have been doing less with more i.e. fewer new novel therapies with alot more money.  Ultimately, the increased money spent on fewer new products means higher prices to compensate for an evaporating reservoir of multiple sources of revenue.  The...

The Bush Administration's  most recent report on the future of the Medicare and Social Security Programs released this week is at least not worse than it was a year ago.  That's the good news.  However, the bad news is that it is no better.  The Medicare Hospital Trust Fund is expected...

While pharmaceutical companies raised prices at a higher level than general inflation, implementing price controls is not the appropriate means to control drug spend.  More effort needs to be placed on clinical trials and the demonstration of efficacy and value prior to a products release. ...

As the population age, more and more patients depend on medicare for their medical care. I do not know how they are going to afford the medication cost with bad economy and elevated drug price

A delay in instituting aggressive antirheumatic medications such as the biologic response modifiers has long term implications in irreversible joint damage. Cost considerations (particularly with the looming potential of "universal healthcare" under a new administrations promises) with exponentially...

The merger will either freeze the market or provide huge upside for the NEWCO due to Practice Management and EMR syneergies.

This is an acknowledgement that a majority of AllScripts' EMR business was generated by their now defunct partnership with IDX. It is also an acknowledgement that AllScript's purchase of A4 did not fill the void caused by the departure of the IDX relationship after IDX was purchased by GE (who have...

R&D spending is what provides for new drugs to be created years from now.

Pfizer will loose no matter what, even if they are vindicated, as they have lost time and money in court.